Author:
Wei Shizhang,Ma Xiao,Niu Ming,Wang Ruilin,Yang Tao,Wang Dan,Wen Jianxia,Li Haotian,Zhao Yanling
Subject
Pharmacology (medical),Pharmacology
Reference28 articles.
1. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond;Beuers;J. Hepatol.,2015
2. Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH;Bjursell;PLoS One,2013
3. Drug-induced cholestasis: mechanisms, models, and markers;Chatterjee;Curr. Drug Metab.,2018
4. Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid: a novel FXR agonist for the treatment of dyslipidemia;Genin;J. Med. Chem.,2015
5. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver;Gerloff;J. Biol. Chem.,1998
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献